New hope for rare leukemia: ruxolitinib trial launches
NCT ID NCT05592015
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether the drug ruxolitinib can shrink tumors in 30 adults with T-cell large granular lymphocyte leukemia, a rare blood cancer. Ruxolitinib works by blocking enzymes that cancer cells need to grow. The study will measure how many patients respond to treatment and track side effects and quality of life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Ruxolitinib (a drug that blocks enzymes helping cancer cells grow)
- What this could lead to
- If successful, this could offer a new treatment option for people with this rare leukemia, potentially shrinking tumors and improving quality of life.
- What could go wrong
- This is a small, early-phase trial with only 30 participants, so results may not apply to everyone. Side effects from ruxolitinib are possible, and the drug may not work for all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for T-CELL LARGE GRANULAR LYMPHOCYTE LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dana-Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Ohio State University Comprehensive Cancer Center
RECRUITINGColumbus, Ohio, 43210, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.